IVF Success Rates in India — by Age, Clinic & Cycle

Important: These are population-level estimates, not personal predictions. A 38-year-old patient may fall anywhere within or outside her age group's range — depending on AMH, diagnosis, embryo quality, and clinic lab competence. All variables are covered in the sections below.

Section 1 — Understanding IVF Success Rate Metrics

Most clinics quote one statistic as their "success rate." The problem: that number can mean four completely different things — and the difference between the highest and lowest figure for the same clinic can be 20–25 percentage points.

The Four Metrics — What Each Actually Means

• Clinical Pregnancy Rate: Confirmed heartbeat at 6–7 weeks. Most commonly quoted by Indian clinics — honest but incomplete. Miscarriage occurs in 15–25% of confirmed IVF pregnancies under 35, rising to 40–60% above 40. A 60% clinical pregnancy rate clinic may have a live birth rate of 48%.
• Biochemical Pregnancy Rate: Positive beta-hCG with no confirmed heartbeat. Embryos that implanted briefly then failed. Almost never disclosed by clinics. When a clinic cannot tell you their biochemical pregnancy rate, that is meaningful.
• Ongoing Pregnancy Rate: Pregnancy confirmed past 12 weeks. Rarely quoted but more predictive of live birth than clinical pregnancy rate.
• Live Birth Rate (LBR): The only number that answers the question every patient actually has: Will I have a baby? Delivery of a live infant after 24 weeks gestation. Mandatorily published in the US (SART) and UK (HFEA). Not required in India.

The rule to apply at every clinic consultation: When a clinic says "our success rate is 65%," ask three questions: Is that your live birth rate or clinical pregnancy rate? — Is it per cycle started or per embryo transfer? — What age group does that cover? A clinic that cannot or will not answer all three is telling you something important.

Why India Has No Mandatory Public Success Rate Data

The practical consequences of India's missing data infrastructure:

• Clinics self-report success rates on their websites with no independent verification
• Patient selection inflates apparent rates — clinics that decline difficult cases have structurally higher reported rates than those treating all comers
• "Average IVF success rate in India" as a single figure is statistically meaningless — it aggregates clinics with 25% and 65% live birth rates
• You cannot compare clinics across cities using publicly available data the way you can in the US or UK

This does not mean Indian IVF outcomes are poor. Leading Indian centres — high-volume, NABH-accredited, with dedicated embryology teams — achieve outcomes that track international benchmarks within 5–10 percentage points. The problem is information asymmetry, not capability.

The SART Benchmark — Why We Use It as Reference

Because India lacks published aggregate outcome data, this guide uses SART 2022 national data as its primary reference baseline. Not because Indian and US patient populations are identical — they are not — but because SART provides the most granular, independently verified, publicly accessible dataset by age group, cycle type, and diagnosis available in English.

Section 2 — IVF Success Rates by Age in India

Age is the single strongest predictor of IVF outcome. More than AMH. More than diagnosis. More than clinic quality. Age directly determines egg chromosomal quality, which determines embryo viability, which determines implantation and live birth probability.

Own Egg IVF — Live Birth Rate by Age Group

Sources: SART 2022 national data; adjusted for Indian patient profiles based on published JOGI and ESHRE literature. LBR = Live Birth Rate.

The 35-year clinical threshold: Age 35 is the point at which chromosomal error rates in eggs cross 40% — the level at which per-cycle success rates begin declining at a rate that becomes clinically significant year-over-year. A patient who is 34 today and waits 18 months before starting IVF may move from the 44–52% bracket to the 35–45% bracket — a difference of approximately 8–10 percentage points per transfer. Time is the one variable in IVF that cannot be compensated for with protocol adjustments.

The Biology Behind the Age Decline — Aneuploidy

The decline in IVF success with age is not about running out of eggs. It is about chromosomal integrity — specifically, the increasing rate of errors during the final stages of egg maturation (meiosis I and II), where chromosome pairs must separate correctly.

Aneuploidy is the term for an embryo that has the wrong number of chromosomes. Aneuploid embryos either fail to implant, cause early miscarriage, or in rare cases result in a chromosomal condition (trisomy 21 / Down syndrome being the most survivable).

Donor Egg IVF — When Recipient Age Becomes Irrelevant

When donor eggs are used, the recipient's age stops being the primary success rate determinant. What matters instead is the egg donor's age and the recipient's uterine health. Success tracks the egg source, not the woman carrying the pregnancy.

In India under the ART Regulation Act 2021: Egg donors must be aged 23–35. Donation is anonymous — no identifying information shared with the recipient. Donors are screened for genetic conditions, infectious diseases, and psychological suitability. Legal parentage is firmly established in favour of the recipient couple from birth.

Section 3 — What Actually Affects Your IVF Success Rate

Age sets the ceiling. Everything below either raises or lowers your probability within that ceiling. This section covers the five variables that reproductive endocrinologists weigh alongside age when estimating your specific prognosis.

Ovarian Reserve — AMH and AFC

AMH and AFC are quantity predictors, not quality predictors. A low AMH does not mean IVF will fail. It means fewer eggs will be retrieved per cycle, which reduces the number of embryos created, which reduces the probability of having at least one viable blastocyst for transfer. The per-transfer success rate of that blastocyst — once you have it — is determined by age and embryo quality, not by AMH.

The critical clinical distinction: Once a euploid blastocyst is transferred, AMH is entirely irrelevant to outcome. A patient with AMH 0.4 ng/mL who produces one good blastocyst has the same per-transfer success rate as a patient with AMH 4.0 ng/mL transferring the same grade embryo. Low AMH reduces your chances of reaching transfer — it does not reduce what happens after transfer.

Diagnosis-Specific IVF Success Rates

The underlying cause of infertility determines how IVF interacts with your specific physiology — ovarian response, fertilisation, implantation, and miscarriage risk all vary by diagnosis.

The endometriosis note every patient needs: Endometriosis is a progressive disease. Stage III–IV disease can reduce ovarian reserve by the equivalent of 5–8 years of biological aging. A 34-year-old with Stage III endometriosis may have the ovarian reserve of a 40–42-year-old. This is why reproductive endocrinologists often recommend earlier IVF referral for confirmed endometriosis — not as an overreaction, but because the reserve window is narrower and closing faster.

Embryo Quality — The Gardner Grading Impact

The quality of the embryo transferred is the most directly controllable per-transfer success variable. This is why Day 5 blastocyst culture — rather than Day 3 transfer — is now the global standard of care at high-volume centres.

The clinical reality grade tables alone do not show: A 4BB embryo transferred into a well-prepared trilaminar endometrium (8–12mm) in a 33-year-old with no uterine pathology will outperform a 4AA embryo transferred into a patient with an inadequately prepared endometrium or an undetected uterine septum. Embryo grade predicts implantation potential under optimal conditions. The endometrial environment is equally important.

Blastocyst rate as a lab quality marker: In a high-quality embryology lab, 45–60% of 2PN (fertilised) embryos should reach a usable blastocyst by Day 5–6. If your clinic cannot tell you their blastocyst development rate — or if it is below 35% — that is a direct indicator of lab quality more meaningful than any headline success rate figure.

BMI and Its Impact on IVF Outcomes

BMI affects IVF success through three independent mechanisms: ovarian response to stimulation, endometrial receptivity, and miscarriage risk.

The PCOS-specific BMI interaction: PCOS already carries elevated miscarriage risk through LH excess and insulin resistance. When PCOS co-exists with BMI above 30, miscarriage rates following IVF can reach 30–40% compared to 15–20% in normal-BMI PCOS patients. A 5–10% body weight reduction before starting IVF — achievable in 2–3 months — reduces insulin resistance, lowers LH, and measurably improves both embryo quality and endometrial receptivity.

Sperm DNA Fragmentation Index (DFI) — The Hidden Male Factor

Standard semen analysis measures count, motility, and morphology. It does not measure DNA integrity — the structural quality of genetic material inside each sperm. This is why a male partner with a "normal" semen analysis can still be contributing to IVF failure.

• DFI testing is not part of the standard pre-IVF workup at most Indian clinics — it requires a separate sperm DNA fragmentation test (SCSA or TUNEL assay), costing ₹3,000–₹8,000
• TESA (testicular sperm aspiration) retrieves sperm directly from the testis, bypassing epididymal maturation where DNA damage accumulates — testicular sperm has DFI 20–30 points lower than ejaculated sperm from the same patient
• For men with DFI above 40%, TESA combined with ICSI is the evidence-supported intervention — not simply repeating another cycle with ejaculated sperm

When to proactively test DFI: IVF failed despite good embryo grades · blastocyst development consistently arrests at Day 3–4 · borderline morphology below 2% · male partner is a heavy smoker, above 45, or has a history of varicocele.

Section 4 — Fresh Transfer vs FET: Which Has Higher Success?

For most patients, FET outcomes are equivalent to or better than fresh transfer. The reasons are mechanistic, not arbitrary — understanding them helps you evaluate your clinic's recommendation.

Why Fresh Transfer Is Physiologically Harder Than It Looks

During an ovarian stimulation cycle, supraphysiological estrogen levels — sometimes 10–15x the normal peak — create a hormonal environment that has no equivalent in natural reproduction. The endometrium responds by advancing its developmental stage faster than normal. By the time egg retrieval occurs, the endometrium may already be 1–2 days ahead of where a Day 5 blastocyst needs it to be. This mismatch is called implantation asynchrony — one of the primary reasons fresh transfer fails in otherwise good-quality cycles.

In a FET cycle, the endometrium is prepared from scratch in a controlled hormonal environment — precisely synchronised to the blastocyst's developmental stage. Additional reasons FET outperforms fresh:

• Patient has had 4–6 weeks to recover from stimulation and retrieval
• Progesterone levels at transfer can be more precisely controlled and monitored
• Clinic can time transfer to the exact day of endometrial readiness — not around the retrieval schedule
• For high responders, OHSS risk of fresh transfer is eliminated entirely with freeze-all

Fresh vs FET — Live Birth Rate Comparison

The PCOS freeze-all standard: In PCOS, the combination of high follicle counts and insulin resistance creates severe OHSS risk with fresh transfer. A GnRH agonist trigger followed by freeze-all eliminates OHSS risk almost entirely. Freeze-all + medicated FET consistently produces live birth rates 15–20 percentage points higher than fresh transfer in PCOS patients. This is now the ESHRE recommendation and practice standard at leading Indian centres.

When fresh transfer remains appropriate: Stimulation response was mild (estradiol below 2,000 pg/mL, fewer than 8 eggs) · the patient has very few embryos and freezing risk is a concern · endometrium is confirmed trilaminar at 8mm+ with normal progesterone · patient cannot wait for a FET cycle due to age or logistical constraints.

Natural FET vs Medicated FET — The Protocol Within FET

Day 3 vs Day 5 Transfer — The Blastocyst Advantage

Why blastocyst culture improves outcomes:

• Biological selection: an embryo that cannot sustain itself to Day 5 would not have implanted in a natural pregnancy either — arrest in culture reveals non-viability before transfer
• Better embryo-endometrium synchrony: a Day 5 blastocyst transferred on Day 5 of progesterone matches the natural 5-day post-ovulation implantation window
• Superior morphological grading: at Day 5, expansion stage, inner cell mass, and trophectoderm quality are all assessable using the Gardner scale — far more predictive than Day 3 cell count alone

The 4-embryo decision rule: 4 or more good Day 3 embryos → culture to Day 5. Fewer than 3 → discuss Day 3 transfer with your embryologist to avoid losing all embryos in culture. This decision should be made jointly, with specific numbers, before retrieval day — not as a surprise call on Day 3.

Section 5 — IVF Success Rates by Cycle Number

One of the most damaging misconceptions in fertility care is that IVF either works in the first cycle or it does not work at all. The clinical data shows the opposite: most patients who eventually succeed do so across multiple cycles. Stopping after one failed cycle is the single most common reason patients never achieve the live birth that statistics show was within reach.

Cumulative Live Birth Rate — The Most Important Number You Are Never Told

Based on SART 2022 cumulative data. Assumes frozen embryos available from stimulation cycle for cycles 2+.

Why Cycle 2 and 3 Still Work — The Protocol Adjustment Effect

A failed IVF cycle is not just a loss — it is the most detailed diagnostic data your doctor will ever have about your specific response. After cycle 1, the clinic knows:

• Exactly how many follicles you produced at what stimulation dose — and your precise estradiol trajectory
• Your fertilisation rate and embryo development pattern to Day 3 and Day 5
• Your endometrial thickness, pattern, and progesterone level on transfer day
• Whether the transfer itself was technically straightforward or difficult (canal direction, cervical resistance)

This data drives meaningful protocol adjustments for cycle 2 — different starting doses, trigger strategy, luteal support protocol, or transfer timing. Patients who adjust protocol between cycles consistently outperform those who repeat the identical approach.

When to Consider Stopping — Honest Clinical Guidance

Cumulative success rates do not continue rising indefinitely. After 4–6 cycles with no pregnancy, a fundamental reassessment is warranted — not a seventh attempt under the same approach.

• Repeated euploid failure: If PGT-A confirms chromosomally normal embryos have been transferred 3+ times without implantation, the issue is endometrial receptivity — not embryo quality. ERA testing, immune evaluation, and hysteroscopy take priority before the next transfer.
• Consistently no blastocysts: If repeated cycles yield fertilised embryos that all arrest before Day 5, the issue may be mitochondrial egg quality that cannot be resolved with higher doses. Donor eggs are the most likely path to success.
• POI (premature ovarian insufficiency): When AMH drops below 0.1 ng/mL and AFC consistently shows 0–1 follicles, own-egg IVF success rates fall below 5%. Most reproductive endocrinologists advise transitioning to donor eggs rather than continuing own-egg cycles.
• Age above 43 with poor response: Each year above 43 adds approximately 5–8% more aneuploid embryos to an already very high baseline. When no euploid embryos are produced across 2–3 cycles, the statistical probability of success with own eggs becomes very low.

The freeze-all cumulative advantage: When one stimulation cycle produces multiple blastocysts — all vitrified — the cumulative success calculation changes dramatically. One retrieval can yield 3–5 FET attempts, each at 40–58% live birth rate per transfer. Four transfers at 48% each = approximately 93% cumulative probability of at least one live birth.

Section 6 — How to Read a Clinic's Published Success Rate

This is the section most fertility guides skip entirely. It is the section that will actually protect you from making a ₹1.5–3 lakh decision based on a number that tells you very little.

The Six Questions to Ask Every Clinic

Red Flags in Clinic Success Rate Claims

What ICMR registration actually means: Registration confirms minimum infrastructure standards and qualified medical director. It does NOT confirm outcomes, embryology lab quality, patient selection practices, or ethical billing. Registration is the floor, not the ceiling. The six questions above are what separate a minimum-standard clinic from a genuinely high-quality centre.

Section 7 — Realistic Expectations by Patient Profile

This section consolidates everything above into a single reference decision table. Find the row that most closely matches your situation — age, diagnosis, and AMH — and read across.

Every number in this guide is a population probability, not a personal prediction. A 38-year-old in the "18–28% per transfer" row is not doomed to a 22% chance. She is in a distribution — some patients in that row succeed on their first transfer; others do not succeed at all. The number describes the group, not the individual. What improves your personal probability within that range: a high-quality embryology lab, a protocol tailored to your response, a technically excellent transfer, and a doctor who adjusts between cycles rather than repeating the same approach.

Section 8 — Frequently Asked Questions